These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16651060)

  • 21. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies.
    Lanas A; Hunt R
    Ann Med; 2006; 38(6):415-28. PubMed ID: 17008305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
    Targownik LE; Metge CJ; Leung S; Chateau DG
    Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
    van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs.
    Mosis G; Stijnen T; Castellsague J; Dieleman JP; van der Lei J; Stricker BH; Sturkenboom MC
    Arthritis Rheum; 2006 Aug; 55(4):537-42. PubMed ID: 16874797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coxibs: a significant therapeutic opportunity.
    Gatti D; Adami S
    Acta Biomed; 2010 Dec; 81(3):217-24. PubMed ID: 22530460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cardiovascular and gastrointestinal safety of NSAIDs].
    van den Bemt P; Tjwa ET; van Oijen MG
    Ned Tijdschr Geneeskd; 2014; 158():A7311. PubMed ID: 24713339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
    Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
    Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis.
    Jarupongprapa S; Ussavasodhi P; Katchamart W
    J Gastroenterol; 2013 Jul; 48(7):830-8. PubMed ID: 23208017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NSAID-associated dyspepsia and ulcers: a prospective cohort study in primary care.
    Hollenz M; Stolte M; Leodolter A; Labenz J
    Dig Dis; 2006; 24(1-2):189-94. PubMed ID: 16699277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonsteroidal anti-inflammatory drugs.
    Tseng CC; Wolfe MM
    Med Clin North Am; 2000 Sep; 84(5):1329-44. PubMed ID: 11026931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dyspepsia in non-steroidal anti-inflammatory drug users and the effect of preventive measures.
    Lee HL; Chua SS; Mahadeva S
    J Dig Dis; 2018 Jun; 19(6):342-349. PubMed ID: 29732728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal.
    Sukel MP; van der Linden MW; Chen C; Erkens JA; Herings RM
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):9-19. PubMed ID: 17963198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature.
    Weberschock TB; Müller SM; Boehncke S; Boehncke WH
    Arch Dermatol Res; 2007 Jul; 299(4):169-75. PubMed ID: 17492455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A COX-2-specific inhibitor plus a proton-pump inhibitor: is this a reasonable approach to reduction in NSAIDs' GI toxicity?
    Cryer B
    Am J Gastroenterol; 2006 Apr; 101(4):711-3. PubMed ID: 16635218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
    Laine L
    Rev Gastroenterol Disord; 2004; 4 Suppl 4():S33-41. PubMed ID: 15580145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis.
    Ribaldone DG; Fagoonee S; Astegiano M; De Angelis C; Smedile A; Caviglia GP; Petrini E; Greco A; Pellicano R
    Pain Physician; 2015 Nov; 18(6):599-607. PubMed ID: 26606012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.